{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:38:28Z","timestamp":1793723908288,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801294"],"award-info":[{"award-number":["81801294"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81420108014"],"award-info":[{"award-number":["81420108014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Post-Doctor Research Project, West China Hospital Sichuan University China","award":["2018HXBH023"],"award-info":[{"award-number":["2018HXBH023"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2017M620427"],"award-info":[{"award-number":["2017M620427"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2018SCU12038"],"award-info":[{"award-number":["2018SCU12038"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&D Program of China","award":["2018YFC1311405"],"award-info":[{"award-number":["2018YFC1311405"]}]},{"name":"Disciplines of Excellence, West China Hospital, Sichuan University","award":["ZY2017305"],"award-info":[{"award-number":["ZY2017305"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.eplepsyres.2019.05.015","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T03:04:05Z","timestamp":1558667045000},"page":"144-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Attenuation of retinal nerve fibre layer in people with epilepsy receiving valproate"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6835-8664","authenticated-orcid":false,"given":"Weixi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-5237","authenticated-orcid":false,"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-4125","authenticated-orcid":false,"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0005","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/112067211002000419","article-title":"Detecting retinal vigabatrin toxicity in patients with partial symptomatic or cryptogenic epilepsy","volume":"20","author":"Akcakaya","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.seizure.2009.02.003","article-title":"Retinal ganglion cell toxicity due to oxcarbazepine and valproic acid treatment in rat","volume":"18","author":"Aktas","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0731-7085(91)80200-S","article-title":"Study of bioequivalence of magnesium and sodium valproates","volume":"9","author":"Balbi","year":"1991","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0020","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/jnnp-2015-310521","article-title":"Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy","volume":"87","author":"Balestrini","year":"2016","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","article-title":"Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies","volume":"25","author":"Blaheta","year":"2005","journal-title":"Medicinal research reviews"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pediatrneurol.2015.02.016","article-title":"An Evaluation of Peripapillary Retinal Nerve Fiber Layer Thickness in Children With Epilepsy Receiving Treatment of Valproic Acid","volume":"53","author":"Dereci","year":"2015","journal-title":"Pediatric neurology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/15569527.2014.930748","article-title":"Ciliary body toxicities of systemic oxcarbazepine and valproic acid treatments: electron microscopic study","volume":"34","author":"Goktas","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archopht.121.1.41","article-title":"Macular thickness changes in glaucomatous optic neuropathy detected using optical coherence tomography","volume":"121","author":"Greenfield","year":"2003","journal-title":"Archives of ophthalmology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0050","first-page":"262","article-title":"Visual field loss associated with vigabatrin: quantification and relation to dosage","volume":"42","author":"Hardus","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1528-1157.2000.tb00212.x","article-title":"Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication","volume":"41","author":"Hardus","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0060","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1046\/j.1528-1157.2002.00502.x","article-title":"Patients treated with vigabatrin exhibit central visual function loss","volume":"43","author":"Hilton","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1059-1311(03)00082-7","article-title":"The effect of antiepileptic drugs on visual performance","volume":"13","author":"Hilton","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archopthalmol.2011.1576","article-title":"Effect of race, age, and axial length on optic nerve head parameters and retinal nerve fiber layer thickness measured by Cirrus HD-OCT","volume":"130","author":"Knight","year":"2012","journal-title":"Archives of ophthalmology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ophtha.2008.09.047","article-title":"Nasal Retinal Nerve Fiber Layer Attenuation: A Biomarker for Vigabatrin Toxicity","volume":"116","author":"Lawthom","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1528-1167.2006.00505.x","article-title":"Retinal nerve fiber layer and macular thickness in adolescents with epilepsy treated with valproate and carbamazepine","volume":"47","author":"Lobefalo","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS drugs"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","article-title":"Vigabatrin visual toxicity: evolution and dose dependence","volume":"42","author":"Malmgren","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0091-3057(81)90004-6","article-title":"Pharmacologic analysis of sodium valproate-induced suppression of secondary components of visual evoked potentials in albino rats","volume":"15","author":"Myslobodsky","year":"1981","journal-title":"Pharmacology, biochemistry, and behavior"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0013-4694(81)90028-6","article-title":"Suppression by sodium valproate of gamma-vinyl GABA-induced facilitation of visual evoked potentials in rats","volume":"52","author":"Myslobodsky","year":"1981","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0105","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/bjo.84.6.622","article-title":"Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers","volume":"84","author":"Nousiainen","year":"2000","journal-title":"The British journal of ophthalmology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archopht.1991.01080010079037","article-title":"Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss","volume":"109","author":"Sommer","year":"1991","journal-title":"Archives of ophthalmology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.seizure.2005.04.010","article-title":"Visual function in epilepsy patients treated with initial valproate monotherapy","volume":"14","author":"Sorri","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0920-1211(97)00062-4","article-title":"The influence of established and new antiepileptic drugs on visual perception. II. A controlled study in patients with epilepsy under long-term antiepileptic medication","volume":"29","author":"Steinhoff","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0125","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1042\/BST0371126","article-title":"Structure-function studies for the panacea, valproic acid","volume":"37","author":"Terbach","year":"2009","journal-title":"Biochemical Society transactions"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1528-1157.2002.17801.x","article-title":"Visual field constriction in 91 Finnish children treated with vigabatrin","volume":"43","author":"Vanhatalo","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pediatrneurol.2007.03.001","article-title":"Antiepileptic drugs and visual function","volume":"36","author":"Verrotti","year":"2007","journal-title":"Pediatric neurology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0887-8994(00)00219-8","article-title":"Effects of antiepileptic drugs on evoked potentials in epileptic children","volume":"23","author":"Verrotti","year":"2000","journal-title":"Pediatric neurology"},{"key":"10.1016\/j.eplepsyres.2019.05.015_bib0150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1167\/iovs.05-0854","article-title":"Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer","volume":"47","author":"Wild","year":"2006","journal-title":"Investigative ophthalmology & visual science"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111930035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111930035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:42:40Z","timestamp":1760276560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012111930035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":30,"alternative-id":["S092012111930035X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.05.015","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attenuation of retinal nerve fibre layer in people with epilepsy receiving valproate","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}